Publications - 'R'
Publications 76 - 100 de 1476
| Titre | DOI |
|---|---|
|
Random Walk in a N-Cube Without Hamiltonian Cycle to Chaotic Pseudorandom Number Generation: Theoretical and Practical Considerations S. Contassot-Vivier; J.F. Couchot; C. Guyeux; P.C. Heam 2017 |
10.1142/S0218127417500146 |
|
Random Walks on Finite Quantum Groups I. Baraquin 2020 |
10.1007/s10959-019-00916-x |
|
Randomised controlled trial demonstrates that fermented infant formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides reduces the incidence of infantile colic Y. Vandenplas; T. Ludwig; H. Bouritius; P. Alliet; D. Forde; S. Peeters; F. Huet; J. Hourihane 2017 |
10.1111/apa.13844 |
|
Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naive patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study A. Thiery-Vuillemin; G. Gravis; C. Schlurmann; E. Bompas; F. Rolland; M. Gross-Goupil; Y.A. Vano; A. Guillot; P. Barthelemy; C. Joly; M. Laramas; L.M. Dourthe; T. Maurina; G. Petithuguenin; K. Taillandy; A. Meurisse; D. Vernerey; L. Albiges 2020 |
10.1016/j.annonc.2020.08.792 |
|
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial C. Le Tourneau; X. Paoletti; N. Servant; I. Bieche; D. Gentien; R. Frio; A. Vincent-Salomon; V. Servois; J. Romejon; O. Mariani; V. Bernard; P. Huppe; G. Pierron; F. Mulot; C. Callens; J. Wong; C. Mauborgne; E. Rouleau; C. Reyes; E. Henry; Q. Leroy; P. Gestraud; P. La Rosa; L. Escalup; E. Mitry; O. Tredan; J.P. Delord; M. Campone; A. Goncalves; N. Isambert; C. Gavoille; M. Kamal 2014 |
10.1038/bjc.2014.211 |
|
Randomised, prospective, medicoeconomic nationwide French study of islet transplantation in patients with severely unstable type 1 diabetes: the STABILOT study protocol S. Lablanche; S. David-Tchouda; J. Margier; E. Schir; A. Wojtusciszyn; S. Borot; L. Kessler; E. Morelon; C. Thivolet; F. Pattou; M.Christine Vantyghem; T. Berney; P.Y. Benhamou 2017 |
10.1136/bmjopen-2016-013434 |
|
Randomized controlled trial comparing embryo culture in two incubator systems: G185 K-System versus EmbryoScope J. Barberet; J. Chammas; C. Bruno; E. Valot; C. Vuillemin; L. Jonval; C. Choux; P. Sagot; A. Soudry; P. Fauque 2018 |
10.1016/j.fertnstert.2017.10.008 |
|
Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE) A. De Parisot; L. Kodjikian; M.H. Errera; N. Sedira; E. Heron; L. Perard; P.L. Cornut; C. Schneider; S. Riviere; P. Olle; G. Pugnet; P. Cathebras; P. Manoli; B. Bodaghi; D. Saadoun; S. Baillif; N. Tieulie; M. Andre; F. Chiambaretta; N. Bonin; P. Bielefeld; A. Bron; F. Mouriaux; B. Bienvenu; S. Vicente; S. Bin; C. Broussolle; E. Decullier; P. Seve; U.L.I.S.S.E. Grp 2017 |
10.1016/j.ajo.2017.03.029 |
|
Randomized Controlled Trial of a Healthy Lifestyle Intervention Among Smokers With Psychotic Disorders A.L. Baker; R. Richmond; F.J. Kay-Lambkin; S.L. Filia; D. Castle; J.M. Williams; T.J. Lewin; V. Clark; R. Callister; N. Weaver 2015 |
10.1093 |
|
Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part M. Hebbar; A. Heurgue-Berlot; V. Boige; K. Le Malicot; B. Bernard-Chabert; C. Marcus; S. Dharancy; G. Sergent; J.M. Perarnau; F. Ehrhard; I. Ollivier-Hourmand; J. Vergniol; P. Michel; J. Edeline; Y. Rinaldi; J.F. Seitz; C. Lepage; T. De Baere 2015 |
10.1016/S0959-8049(16)31221-7 |
|
Randomized Phase 3 Trial of Dose Escalation (80 vs 70 Gy) in High-Risk Prostate Cancers Combined With Long-term Androgen Deprivation: GETUG-AFU 18 Trial, Acute and 1-Year Toxicities C. Hennequin; P.M. Richaud; L. Roca; M. Silva; I. Latorzeff; V. Beckendorff; C. Carrie; A. Benyoucef; A. Hasbini; S. Supiot; P. Ronchin; T. Wachter; D. Azria; P.E. Cailleux; L. Cormier; M. Habibian; G. Delaroche 2015 |
10.1016/j.ijrobp.2015.07.107 |
|
Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial J. Mazieres; F. Barlesi; I. Rouquette; B. Besse; I. Monnet; C. Audigier-Valette; A. Toffart; A. Renault; S. Moreau; S. Hiret; B. Mennecier; D. Debieuvre; V. Westeel; P. Masson; A. Madroszyk; E. Amour; F. Morin; G. Zalcman; D. Moro-Sibilot; P.J. Souquet 2018 |
10.1016/j.jtho.2018.08.622 |
|
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission X. Thomas; S. de Botton; S. Chevret; D. Caillot; E. Raffoux; E. Lemasle; J.P. Marolleau; C. Berthon; A. Pigneux; N. Vey; O. Reman; M. Simon; C. Recher; J.Y. Cahn; O. Hermine; S. Castaigne; K. Celli-Lebras; N. Ifrah; C. Preudhomme; C. Terre; H. Dombret 2017 |
10.1200/JCO.2016.70.4551 |
|
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial L. Belin; M. Kamal; C. Mauborgne; C. Plancher; F. Mulot; J.P. Delord; A. Goncalves; C. Gavoille; C. Dubot; N. Isambert; M. Campone; O. Tredan; F. Ricci; M. Alt; D. Loirat; M.P. Sablin; X. Paoletti; V. Servois; C. Le Tourneau 2017 |
10.1093/annonc/mdw666 |
|
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Results of the SHIVA trial C. Le Tourneau; J.P. Delord; A. Goncalves; C. Gavoille; C. Dubot; N. Isambert; M. Campone; O. Tredan; C. Mauborgne; S. Armanet; N. Servant; I. Bieche; V. Bernard; D. Gentien; P. Jezequel; V. Attignon; S. Boyault; A. Vincent-Salomon; M. Kamal; X. Paoletti 2015 |
|
|
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial J. Mazieres; F. Barlesi; I. Rouquette; O. Molinier; B. Besse; I. Monnet; C. Audigier-Valette; Aclaire Toffart; P.Aldo Renault; S. Fraboulet; S. Hiret; B. Mennecier; D. Debieuvre; V. Westeel; P. Masson; A. Madroszyk-Flandin; E. Pichon; A.B. Cortot; E. Amour; F. Morin; G. Zalcman; D. Moro-Sibilot; P.J. Souquet 2020 |
10.1158/1078-0432.CCR-19-3056 |
|
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial. J. Mazieres; F. Barlesi; I. Rouquette; B. Besse; I. Monnet; C. Audigier-Valette; A.Claire Toffart; P.A. Renault; S.Moreau Fraboulet; S. Hiret; B. Mennecier; D. Debieuvre; V. Westeel; P. Masson; A. Madroszyk; E. Amour; F. Morin; G. Zalcman; D. Moro-Sibilot; P.Jean Souquet 2018 |
10.1200/JCO.2018.36.15_suppl.9097 |
|
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial L. Dahan; N. Williet; K. Le Malicot; J.M. Phelip; J. Desrame; O. Bouche; C. Petorin; D. Malka; C. Rebischung; T. Aparicio; C. Lecaille; Y. Rinaldi; A. Turpin; A.L. Bignon; J.B. Bachet; J.F. Seitz; C. Lepage; E. Francois; P.R.O.D.I.G.E.35 Investi Collabora 2021 |
10.1200/JCO.20.03329 |
|
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF(aEuro) B. Chauffert; L. Feuvret; F. Bonnetain; L. Taillandier; D. Frappaz; H. Taillia; R. Schott; J. Honnorat; M. Fabbro; I. Tennevet; F. Ghiringhelli; J.S. Guillamo; X. Durando; D. Castera; M. Frenay; C. Campello; C. Dalban; J. Skrzypski; O. Chinot 2014 |
10.1093/annonc/mdu148 |
|
Randomized Phase III Study Comparing an Early PET Driven Treatment De Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study O. Casasnovas; P. Brice; R. Bouabdallah; G.A. Salles; A. Stamatoullas; J. Dupuis; O. Reman; T. Gastinne; B. Joly; K. Bouabdallah; E. Nicolas-Virelizier; S. Bologna; F. Morschhauser; R. Delarue; H. Farhat; P. Quittet; A. Berriolo-Riedinger; A. Tempescul; V. Edeline; H. Maisonneuve; J.Claude Eisenmann; A. Traverse-Glehen; M. Andre; N. Mounier; M. Meignan; C. Ferme 2015 |
|
|
Randomized Phase III Study Comparing an Early PET Driven Treatment De Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study O. Casasnovas; P. Brice; R. Bouabdallah; G.A. Salles; A. Stamatoullas; J. Dupuis; O. Reman; T. Gastinne; B. Joly; K. Bouabdallah; E. Nicolas-Virelizier; S. Bologna; F. Morschhauser; R. Delarue; H. Farhat; P. Quittet; A. Berriolo-Riedinger; A. Tempescul; V. Edeline; H. Maisonneuve; J.Claude Eisenmann; A. Traverse-Glehen; M. Andre; N. Mounier; M. Meignan; C. Ferme 2015 |
|
|
Randomized phase III study comparing an early PET driven treatment deescalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study. O. Casasnovas; P. Brice; R. Bouabdallah; G.A. Salles; A. Stamatoulas; J. Dupuis; O. Reman; T. Gastinne; B. Joly; K. Bouabdallah; E. Nicolas-Virelizier; P. Feugier; F. Morschhauser; R. Delarue; A. Berriolo-Riedinger; V. Edeline; A. Traverse-Glehen; M. Andre; N. Mounier; M. Meignan 2018 |
10.1200/JCO.2018.36.15_suppl.7503 |
|
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Ca I.B. Vergote; A. Jimeno; F. Joly; D. Katsaros; C. Coens; E. Despierre; C. Marth; M. Hall; C.B. Steer; N. Colombo; A. Lesoin; A. Casado; A. Reinthaller; J. Green; M. Buck; I. Ray-Coquard; A. Ferrero; L. Favier; N.Simon Reed; H. Cure; E. Pujade-Lauraine 2014 |
10.1200/JCO.2013.50.5669 |
|
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02) T. Aparicio; S. Lavau-Denes; J.M. Phelip; E. Maillard; J.L. Jouve; D. Gargot; M. Gasmi; C. Locher; X. Adhoute; P. Michel; F. Khemissa; T. Lecomte; J. Provencal; G. Breysacher; J.L. Legoux; C. Lepere; J. Charneau; J. Cretin; L. Chone; A. Azzedine; O. Bouche; I. Sobhani; L. Bedenne; E. Mitry; F.F.C.D. Investigators 2016 |
10.1093/annonc/mdv491 |
|
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy F. Bridoux; B. Arnulf; L. Karlin; N. Blin; N. Rabot; M. Macro; V. Audard; K. Belhadj; B. Pegourie; P. Gobert; E.Cornec Le Gall; B. Joly; A. Karras; A. Jaccard; K. Augeul-Meunier; S. Manier; B. Royer; D. Caillot; M. Tiab; S. Delbes; F. Suarez; C. Vigneau; S. Caillard; N. Arakelyan-Laboure; D. Roos-Weil; S. Chevret; J.Paul Fermand; M.Y.R.E.Study Grp 2020 |
10.1200/JCO.20.00298 |